First in human RCT of SGLT2 inhibition in non-diabetic kidney disease. In this cross over trial, 6 weeks of dapagliflozin did not lower albuminuria, but did induce acute & reversible declines in GFR
Fascinating data whilst awaiting DAPA-CKD
7
76
137
Replies
Congrats David, Clare, Hiddo & all involved
The absence of an effect on albuminuria is really interesting. Treatment period too short? Heterogeneity with different glomerular diseases & pathways of injury? Yet we know DAPA-CKD stopped early for overwhelming efficacy
0
0
7
@brendonneuen
@ValleAlfonso
@drpatrickholmes
@mvaduganathan
@CristobMorales
@hswapnil
@Nephro_Sparks
@AmarPut
@georgeinstitute
So, a decline in GFR is good?
1
0
0
@PagingDoctorT
Yes if acute & reversible - suggests reduction in intraglomerular pressure, which is a driver of progressive nephron loss. In T2DM, SGLT2i causes an acute decline followed by long term preservation of GFR
2
2
4
@brendonneuen
@ValleAlfonso
@drpatrickholmes
@mvaduganathan
@CristobMorales
@hswapnil
@Nephro_Sparks
@georgeinstitute
Been checking for this trial to be published since December! Thanks!
0
0
2
@brendonneuen
@ValleAlfonso
@drpatrickholmes
@mvaduganathan
@CristobMorales
@hswapnil
@Nephro_Sparks
@georgeinstitute
Need a longer trial (dapa ckd) but this is a nice taster👍🏽 though we already know dapa-ckd has some good news 😉
0
0
5
@brendonneuen
@ValleAlfonso
@drpatrickholmes
@mvaduganathan
@CristobMorales
@hswapnil
@Nephro_Sparks
@AmarPut
@georgeinstitute
Amazing 😉 unexpected
0
0
0
@brendonneuen
@georgeinstitute
@ValleAlfonso
@drpatrickholmes
@mvaduganathan
@CristobMorales
@hswapnil
@Nephro_Sparks
@AmarPut
"EMPA treatment appeared to be safe and was associated with improved kidney outcomes, regardless of these baseline predictive factors or an initial eGFR dip >10%."
0
3
1
@brendonneuen
@ValleAlfonso
@drpatrickholmes
@mvaduganathan
@CristobMorales
@hswapnil
@Nephro_Sparks
@AmarPut
@georgeinstitute
¿Para cuándo los resultados definitivos?
0
0
0